FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2896549747> ?p ?o ?g. }

• W2896549747 endingPage "e0205827" @default.
• W2896549747 startingPage "e0205827" @default.
• W2896549747 abstract "Introduction Anaplastic lymphoma kinase (ALK) rearrangement gene testing is used increasingly to identify patients with advanced non-small-cell lung cancer (NSCLC) who are most likely to benefit from crizotinib. This study was to evaluate the cost-effectiveness of the ALK tests followed by crizotinib compared to the standard chemotherapy in advanced NSCLC from the Chinese healthcare system perspective. Methods A 10-year Markov model was constructed to compare the costs and quality-adjusted life-years (QALYs) of crizotinib with standard chemotherapy, guided by the ALK rearrangement tests: next-generation sequencing (NGS) panel tests and multiplex polymerase chain reaction (PCR) testing. The health states included progression-free survival (PFS), progressed survival, and death. The costs examined included cost of drugs (pemetrexed, standard chemotherapy, salvage chemotherapy, and crizotinib), follow-up, palliative care, supportive care, severe adverse events, and ALK rearrangement testing. Results Under Patient Assistance Program (PAP), the model demonstrated that the patients using NGS panel tests spent US $31,388 and gained 0.780 QALYs, whereas patients using multiplex PCR spent US $31,362 and gained 0.780 QALYs, respectively. The incremental cost-effectiveness ratios of crizotinib with PAP compared to the control strategy were projected at $14,384 (NGS) and $13,740 (multiplex PCR) per QALY gained, respectively. Sensitivity analyses showed the utility of PFS and the costs of crizotinib and pemetrexed were the most impactful factors on the model outcomes. The results were robust to changes in all parameters. Conclusion ALK-rearrangement test positive followed by crizotinib may be cost-effective compared to standard chemotherapy from the Chinese healthcare system perspective when PAP was available." @default.
• W2896549747 created "2018-10-26" @default.
• W2896549747 creator A5004928583 @default.
• W2896549747 creator A5041837471 @default.
• W2896549747 creator A5048954827 @default.
• W2896549747 creator A5085113015 @default.
• W2896549747 date "2018-10-23" @default.
• W2896549747 modified "2023-10-16" @default.
• W2896549747 title "Cost-effectiveness of ALK testing and first-line crizotinib therapy for non-small-cell lung cancer in China" @default.
• W2896549747 cites W1516701418 @default.
• W2896549747 cites W1994747360 @default.
• W2896549747 cites W1996652550 @default.
• W2896549747 cites W2004078003 @default.
• W2896549747 cites W2005244154 @default.
• W2896549747 cites W2055402151 @default.
• W2896549747 cites W2061932411 @default.
• W2896549747 cites W2070487839 @default.
• W2896549747 cites W2077633559 @default.
• W2896549747 cites W2099530756 @default.
• W2896549747 cites W2099904227 @default.
• W2896549747 cites W2100912832 @default.
• W2896549747 cites W2105595798 @default.
• W2896549747 cites W2112621029 @default.
• W2896549747 cites W2126310082 @default.
• W2896549747 cites W2128473443 @default.
• W2896549747 cites W2130356647 @default.
• W2896549747 cites W2131098741 @default.
• W2896549747 cites W2135714170 @default.
• W2896549747 cites W2137210918 @default.
• W2896549747 cites W2138705226 @default.
• W2896549747 cites W2145835533 @default.
• W2896549747 cites W2163351155 @default.
• W2896549747 cites W2168340462 @default.
• W2896549747 cites W2168691181 @default.
• W2896549747 cites W2272984102 @default.
• W2896549747 cites W2296800272 @default.
• W2896549747 cites W2415278120 @default.
• W2896549747 cites W2568327077 @default.
• W2896549747 cites W2626223149 @default.
• W2896549747 cites W3141540903 @default.
• W2896549747 doi "https://doi.org/10.1371/journal.pone.0205827" @default.
• W2896549747 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6198972" @default.
• W2896549747 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30352060" @default.
• W2896549747 hasPublicationYear "2018" @default.
• W2896549747 type Work @default.
• W2896549747 sameAs 2896549747 @default.
• W2896549747 citedByCount "24" @default.
• W2896549747 countsByYear W28965497472019 @default.
• W2896549747 countsByYear W28965497472020 @default.
• W2896549747 countsByYear W28965497472021 @default.
• W2896549747 countsByYear W28965497472022 @default.
• W2896549747 countsByYear W28965497472023 @default.
• W2896549747 crossrefType "journal-article" @default.
• W2896549747 hasAuthorship W2896549747A5004928583 @default.
• W2896549747 hasAuthorship W2896549747A5041837471 @default.
• W2896549747 hasAuthorship W2896549747A5048954827 @default.
• W2896549747 hasAuthorship W2896549747A5085113015 @default.
• W2896549747 hasBestOaLocation W28965497471 @default.
• W2896549747 hasConcept C117643217 @default.
• W2896549747 hasConcept C126322002 @default.
• W2896549747 hasConcept C143998085 @default.
• W2896549747 hasConcept C2776232967 @default.
• W2896549747 hasConcept C2776256026 @default.
• W2896549747 hasConcept C2776694085 @default.
• W2896549747 hasConcept C2777240266 @default.
• W2896549747 hasConcept C2778239845 @default.
• W2896549747 hasConcept C2778347629 @default.
• W2896549747 hasConcept C2779422266 @default.
• W2896549747 hasConcept C71924100 @default.
• W2896549747 hasConceptScore W2896549747C117643217 @default.
• W2896549747 hasConceptScore W2896549747C126322002 @default.
• W2896549747 hasConceptScore W2896549747C143998085 @default.
• W2896549747 hasConceptScore W2896549747C2776232967 @default.
• W2896549747 hasConceptScore W2896549747C2776256026 @default.
• W2896549747 hasConceptScore W2896549747C2776694085 @default.
• W2896549747 hasConceptScore W2896549747C2777240266 @default.
• W2896549747 hasConceptScore W2896549747C2778239845 @default.
• W2896549747 hasConceptScore W2896549747C2778347629 @default.
• W2896549747 hasConceptScore W2896549747C2779422266 @default.
• W2896549747 hasConceptScore W2896549747C71924100 @default.
• W2896549747 hasIssue "10" @default.
• W2896549747 hasLocation W28965497471 @default.
• W2896549747 hasLocation W28965497472 @default.
• W2896549747 hasLocation W28965497473 @default.
• W2896549747 hasLocation W28965497474 @default.
• W2896549747 hasOpenAccess W2896549747 @default.
• W2896549747 hasPrimaryLocation W28965497471 @default.
• W2896549747 hasRelatedWork W1974903221 @default.
• W2896549747 hasRelatedWork W2057269827 @default.
• W2896549747 hasRelatedWork W2162074187 @default.
• W2896549747 hasRelatedWork W2319183095 @default.
• W2896549747 hasRelatedWork W2439017782 @default.
• W2896549747 hasRelatedWork W2533300620 @default.
• W2896549747 hasRelatedWork W2894476389 @default.
• W2896549747 hasRelatedWork W3024984103 @default.
• W2896549747 hasRelatedWork W3044516145 @default.
• W2896549747 hasRelatedWork W2156754168 @default.
• W2896549747 hasVolume "13" @default.

• next